Novo Nordisk wins EU recommendation for label extension of long-acting growth hormone
The EMA’s expert committee has taken a positive stance on the Danish drugmaker’s treatment for children over three years with growth hormone deficiencies.
by marketwire, translated by daniel pedersen
Novo Nordisk’s long-acting growth hormone, Sogroya (somapacitan), has been recommended for an indication expansion by the European Medicines Agency’s (EMA) expert committee, the CHMP.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg)
